ClinicaliQ Trial Snapshot
- A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) — Recruiting • Phase III • NCT06533098.
- A trial testing whether nipocalimab injection safely prevents severe low platelet counts in babies of at-risk pregnant women.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT). Conditions: Thrombocytopenia, Neonatal Alloimmune Interventions: Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 50 participants